Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada

Oncologist

Volumn 19, Issue 8, 2014, Pages 880-885

  Louie, Alexander V ^a,b,c   Rodrigues, George B ^b   Palma, David A ^b   Senan, Suresh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Health policy; Microsimulation model; Non small cell lung cancer; Stereotactic ablative radiotherapy

Indexed keywords

ALGORITHM; ARTICLE; CANADA; CANCER INCIDENCE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC PROCEDURE; SURVIVAL; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE POLICY; LUNG RESECTION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RADIOSURGERY;

CANADA; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HEALTH POLICY; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; QUALITY-ADJUSTED LIFE YEARS; RADIOSURGERY;

EID: 84905509843     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0469     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15: 4-9.
3. Cykert S, Dilworth-Anderson P, Monroe MH et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 2010; 303: 2368-2376.
4. Wisnivesky JP, Bonomi M, Henschke C et al. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest 2005; 128: 1461-1467.
5. Vest MT, Herrin J, Soulos PR et al. Use of new treatment modalities for non-small cell lung cancer care in the Medicare population. Chest 2013; 143: 429-435.
6. Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thorac Surg Clin 2013; 23: 369-381.
7. Guckenberger M, Allgäuer M, Appold S et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: A patterns-of-care and outcome analysis. J Thorac Oncol 2013; 8: 1050-1058.
8. Timmerman R, Paulus R, Galvin J et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076.
9. Varlotto J, Fakiris A, Flickinger J et al. Matchedpair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer 2013; 119: 2683-2691.
10. Senthi S, Lagerwaard FJ, Haasbeek CJ et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis. Lancet Oncol 2012; 13: 802-809.
11. Herder GJ, van Tinteren H, Golding RP et al. Clinical prediction model to characterize pulmonary nodules: Validation and added value of 18Ffluorodeoxyglucose positron emission tomography. Chest 2005; 128: 2490-2496.
12. Verstegen NE, Oosterhuis JW, Palma DA et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): Outcomes of a propensity score-matched analysis. Ann Oncol 2013; 24: 1543-1548.
13. Haasbeek CJ, Palma D, Visser O et al. Earlystage lung cancer in elderly patients: A populationbased study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743-2747.
14. Palma D, Visser O, Lagerwaard FJ et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: A population-based time-trend analysis. J Clin Oncol 2010; 28: 5153-5159.
15. Evans WK, Wolfson MC, Flanagan WM et al. Canadian Cancer Risk Management Model: Evaluation of cancer control. Int J Technol Assess Health Care 2013; 29: 131-139.
16. Evans WK, Wolfson MC, Flanagan WMet al. The evaluation of cancer control interventions in lung cancer usingthe Canadian Cancer Risk Management Model. Lung Cancer Manage 2012; 1: 25-33.
17. Whittemore AS, McMillan A. Lung cancer mortality among U. S. uranium miners: A reappraisal. J Natl Cancer Inst 1983; 71: 489-499.
18. Evans WK, Ung YC, Assouad N et al. Improving the quality of lung cancer care in Ontario: The lung cancer disease pathway initiative. J Thorac Oncol 2013; 8: 876-882.
19. McIntosh CN, Connor Gorber S, Bernier J et al. Eliciting Canadian population preferences for health states using the Classification and Measurement System of Functional Health (CLAMES). Chronic Dis Can 2007; 28: 29-41.
20. Evans WK, Connor Gorber SK, Spence ST et al. Health state descriptors for Canadians: Cancers. Ottawa, Canada: Statistics Canada, 2005.
21. Smith CB, KaleM, Mhango Get al. Comparative outcomes of elderly stage I lung cancer patients treated with segmentectomy via video-assisted thoracoscopic surgery versus open resection. J Thorac Oncol 2014; 9: 383-389.
22. Heitjan DF, Kim CY, Li H. Bayesian estimation of cost-effectiveness from censored data. Stat Med 2004; 23: 1297-1309.
23. Lagerwaard FJ, Verstegen NE, Haasbeek CJ etal. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83: 348-353.
24. Navaratnam S, Kliewer EV, Butler J et al. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010; 70: 110-115.
25. Moghanaki D, Karas T. Surgery versus SABR for NSCLC. Lancet Oncol 2013; 14: e490-e491.
26. Louie AV, Senthi S, Palma DA. Surgery versus SABR for NSCLC. Lancet Oncol 2013; 14: e491.
27. Shah A, Hahn SM, Stetson RL et al. Costeffectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer 2013; 119: 3123-3132.
28. Senan S. Surgery versus stereotactic radiotherapy for patients with early-stage non-small cell lung cancer: More data from observational studies and growing clinical equipoise. Cancer 2013; 119: 2668-2670.
29. Shirvani SM, Jiang J, Chang JY et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012; 84: 1060-1070.
30. Louie AV, Rodrigues G, Hannouf M et al. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: A Markov model-based decision analysis. Int J Radiat Oncol Biol Phys 2011; 81: 964-973.
31. Senthi S, Senan S. Surgery for early-stage lung cancer: Post-operative 30-day versus 90-day mortality and patient-centred care. Eur J Cancer 2014; 50: 675-677.
32. Sundaresan S, McLeod R, Irish J et al. Early results after regionalization of thoracic surgical practice in a single-payer system. Ann Thorac Surg 2013; 95: 472-478; discussion 478-479.
33. Palma D, Lagerwaard F, Rodrigues G et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: Stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012; 82: 1149-1156.
34. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med 1978; 299: 1397-1401.
35. Palma DA, Senan S. Early-stage non-small cell lung cancer in elderly patients: Should stereotactic radiation therapy be the standard of care? Int J Radiat Oncol Biol Phys 2012; 84: 1058-1059.
36. Mitera G, Swaminath A, Rudoler D et al. Costeffectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer. J Oncol Pract 2014; 10: e130-e. 136.
37. Senthi S, Haasbeek CJ, Slotman BJ et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review. Radiother Oncol 2013; 106: 276-282.
38. Sher DJ, Wee JO, Punglia RS. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81: e767-e774.
39. Grutters JP, Kessels AG, Pijls-Johannesma M et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for nonsmall cell lung cancer: A meta-analysis. Radiother Oncol 2010; 95: 32-40.
40. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
41. Wood DE, Eapen GA, Ettinger DS et al. Lung cancer screening. J Natl Compr Canc Netw 2012; 10: 240-265.
42. Bach PB, Mirkin JN, Oliver TK et al. Benefits and harms of CT screening for lung cancer: A systematic review. JAMA 2012; 307: 2418-2429.
43. McWilliams A, Tammemagi MC, Mayo JR et al. Probabilityof cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013; 369: 910-919.
44. Seigneurin A, Field JK, Gachet A et al. A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer. Ann Oncol 2014; 25: 781-789.
45. Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: Surgery or stereotactic ablative radiotherapy? Lancet Oncol 2013; 14: e270-e274.
46. Lund CR, Cao JQ, Liu M et al. The distribution and patterns of practice of stereotactic ablative body radiotherapy in Canada. J Med Imaging Radiat Sci 2014; 45: 8-15.